Plan to post the following comment under the article. Feedback is appreciated.
The results of this randomized trial are presented rather misleadingly.
The authors (Gotaas et al.) have designed a new form of treatment for patients with ME/CFS which they call “interpersonal oriented cognitive behavioral therapy (I-CBT)”. After 8 weeks of treatment the difference between the group that received I-CBT and the control group that was on a waiting list to receive I-CBT, was clinically insignificant.
For the primary outcome of this trial, self-reported physical function on the SF-36, the difference between both groups was 6.8 points, lower than the 10 points the authors had chosen as the minimal important difference. For the secondary outcome of fatigue measured with the Chalder Fatigue Questionnaire, the difference between the I-CBT and waiting list control group was not statistically significant, despite an adequate sample size.
These results indicate that I-CBT is likely an ineffective treatment for patients suffering from ME/CFS. The abstract, however, gives the exact opposite impression stating, for example, that the “I-CBT program improves physical function.” It also concludes that this effect “persist 1 year after baseline”. At that time point (52 weeks post-randomization) there were no longer any outcome measurements for patients in the control group. It is rather misleading to speak of a treatment effect if results are not compared to a control condition.
Lastly, the protocol provided in the supplementary material, lists physical condition VO2 max as a secondary outcome and indicates that it was the intention to publish these data in the main paper (paper 1). It is unclear why the VO2 max data haven’t been published in this paper.